×

Viatris ROE 2010-2024 | VTRS

Current and historical return on equity (ROE) values for Viatris (VTRS) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Viatris ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2024-12-31 $-0.63B $18.64B -3.25%
2024-09-30 $-0.88B $19.79B -4.43%
2024-06-30 $-0.65B $19.52B -3.20%
2024-03-31 $-0.06B $20.01B -0.27%
2023-12-31 $0.05B $20.47B 0.26%
2023-09-30 $1.83B $20.87B 8.75%
2023-06-30 $1.85B $20.84B 9.04%
2023-03-31 $1.90B $20.93B 9.40%
2022-12-31 $2.08B $21.07B 10.32%
2022-09-30 $0.80B $19.18B 4.02%
2022-06-30 $0.76B $19.81B 3.72%
2022-03-31 $0.17B $20.45B 0.81%
2021-12-31 $-1.27B $20.49B -6.02%
2021-09-30 $-1.92B $21.14B -8.86%
2021-06-30 $-2.05B $21.21B -10.48%
2021-03-31 $-1.73B $21.42B -10.07%
2020-12-31 $-0.67B $22.95B -4.58%
2020-09-30 $0.27B $12.55B 2.25%
2020-06-30 $0.27B $11.75B 2.34%
2020-03-31 $0.06B $11.26B 0.54%
2019-12-31 $0.02B $11.88B 0.14%
2019-09-30 $0.05B $11.46B 0.40%
2019-06-30 $0.03B $11.90B 0.28%
2019-03-31 $0.24B $11.89B 1.99%
2018-12-31 $0.35B $12.17B 2.85%
2018-09-30 $0.55B $12.07B 4.30%
2018-06-30 $0.46B $12.21B 3.52%
2018-03-31 $0.72B $13.18B 5.44%
2017-12-31 $0.70B $13.31B 5.44%
2017-09-30 $0.87B $13.29B 7.11%
2017-06-30 $0.66B $12.83B 5.57%
2017-03-31 $0.53B $11.66B 4.74%
2016-12-31 $0.48B $11.12B 4.41%
2016-09-30 $0.26B $11.83B 2.44%
2016-06-30 $0.81B $10.33B 8.02%
2016-03-31 $0.81B $10.28B 8.18%
2015-12-31 $0.85B $9.77B 8.88%
2015-09-30 $0.84B $9.82B 10.62%
2015-06-30 $0.91B $9.57B 14.41%
2015-03-31 $0.87B $9.09B 18.19%
2014-12-31 $0.93B $3.28B 28.09%
2014-09-30 $0.92B $3.41B 28.50%
2014-06-30 $0.58B $3.35B 18.21%
2014-03-31 $0.63B $3.19B 20.54%
2013-12-31 $0.62B $2.96B 20.76%
2013-09-30 $0.61B $3.23B 19.52%
2013-06-30 $0.66B $2.95B 20.54%
2013-03-31 $0.62B $2.89B 18.95%
2012-12-31 $0.64B $3.36B 18.37%
2012-09-30 $0.61B $3.62B 17.24%
2012-06-30 $0.55B $3.20B 15.85%
2012-03-31 $0.56B $3.78B 15.31%
2011-12-31 $0.54B $3.51B 14.49%
2011-09-30 $0.41B $3.49B 11.00%
2011-06-30 $0.36B $3.88B 9.65%
2011-03-31 $0.27B $3.92B 7.57%
2010-12-31 $0.22B $3.62B 6.70%
2010-09-30 $0.22B $3.54B 6.98%
2010-06-30 $0.08B $2.98B 2.46%
2010-03-31 $0.08B $3.18B 2.70%
2009-12-31 $0.09B $3.15B 3.16%
Sector Industry Market Cap Revenue
Medical Medical Services $10.397B $14.739B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $146.516B 27.37
Elevance Health (ELV) United States $98.469B 13.19
CVS Health (CVS) United States $85.419B 12.50
Cencora (COR) United States $53.926B 19.57
DiDi Global (DIDIY) China $23.525B 0.00
Natera (NTRA) United States $19.117B 0.00
BioMerieux (BMXMF) France $14.914B 0.00
ICON (ICLR) Ireland $14.132B 12.84
Solventum (SOLV) United States $13.154B 12.27
Revvity (RVTY) United States $12.712B 21.59
Avantor (AVTR) United States $11.045B 16.21
CochLear (CHEOY) Australia $10.877B 0.00
Doximity (DOCS) United States $10.834B 56.34
EUROFINS SCIENT (ERFSF) Luxembourg $10.609B 0.00
Medpace Holdings (MEDP) United States $9.283B 24.12
Sonic Healthcare (SKHHY) Australia $7.768B 0.00
Charles River Laboratories (CRL) United States $7.697B 14.59
HealthEquity (HQY) United States $7.644B 37.60
Bausch + Lomb (BLCO) Canada $5.111B 23.39
Amplifon S.p.A (AMFPF) Italy $4.961B 26.19
Organon (OGN) United States $3.841B 3.91
Alignment Healthcare (ALHC) United States $3.572B 0.00
Sotera Health (SHC) United States $3.305B 19.11
BrightSpring Health Services (BTSG) United States $3.165B 32.89
Surgery Partners (SGRY) United States $3.031B 34.93
Concentras Parent (CON) United States $2.781B 14.47
GeneDx Holdings (WGS) United States $2.486B 295.22
Ardent Health Partners (ARDT) United States $1.963B 0.00
Progyny (PGNY) United States $1.908B 42.15
Agilon Health (AGL) United States $1.785B 0.00
Premier (PINC) United States $1.760B 11.27
PACS (PACS) United States $1.713B 0.00
GoodRx Holdings (GDRX) United States $1.692B 36.75
Teladoc Health (TDOC) United States $1.382B 0.00
Pediatrix Medical (MD) United States $1.243B 10.42
Establishment Labs Holdings (ESTA) $1.177B 0.00
Ryman Healthcare (RYHTY) New Zealand $1.031B 0.00
CareDx (CDNA) United States $0.984B 16.75
AMN Healthcare Services Inc (AMN) United States $0.934B 7.39
Embecta (EMBC) United States $0.741B 5.08
QDM (QDMI) Hong Kong, SAR China $0.526B 13.77
Auna S.A (AUNA) Luxembourg $0.526B 13.94
Enhabit (EHAB) United States $0.444B 41.86
Sonida Senior Living (SNDA) United States $0.441B 0.00
InnovAge Holding (INNV) United States $0.403B 0.00
SBC Medicals (SBC) United States $0.329B 0.00
DocGo (DCGO) United States $0.269B 11.00
COMPASS Pathways (CMPS) United Kingdom $0.265B 0.00
Nutex Health (NUTX) United States $0.256B 5.10
LifeMD (LFMD) United States $0.243B 0.00
Performant Healthcare (PHLT) United States $0.232B 0.00
Beauty Health (SKIN) United States $0.168B 0.00
Sera Prognostics (SERA) United States $0.139B 0.00
So-Young (SY) China $0.098B 0.00
Biodesix (BDSX) United States $0.091B 0.00
Basel Medical Group (BMGL) Singapore $0.090B 0.00
OncoCyte (OCX) United States $0.088B 0.00
Oncology Institute (TOI) United States $0.086B 0.00
Ascend Wellness Holdings (AAWH) United States $0.075B 0.00
IceCure Medical (ICCM) Israel $0.065B 0.00
NeueHealth (NEUE) United States $0.056B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.026B 0.00
Pheton Holdings (PTHL) China $0.024B 0.00
ModivCare (MODV) United States $0.019B 6.57
SeaStar Medical Holding (ICU) United States $0.011B 0.00
Co-Diagnostics (CODX) United States $0.010B 0.00
Intelligent Bio Solutions (INBS) United States $0.010B 0.00
KindlyMD (KDLY) United States $0.010B 0.00
XWELL (XWEL) United States $0.005B 0.00
BioNexus Gene Lab (BGLC) $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
ISpecimen (ISPC) United States $0.001B 0.00
Aclarion (ACON) United States $0.000B 0.00
Cano Health (CANOQ) United States $0.000B 0.00